Diagnosis and Management of Amyloidosis

Determining Amyloid Type

• The American College of Cardiology recommends identifying the precursor protein type after confirming amyloidosis via Congo red staining, as this dictates treatment strategy and prognosis 1, 2
• Mass spectrometry-based analysis (LC-MS/MS) of the biopsy is the gold standard for amyloid typing with 88% sensitivity and 96% specificity 1, 3
• The American College of Cardiology suggests that if LC-MS/MS is not immediately available, pathological samples with positive Congo red staining should be transferred to an experienced reference laboratory for definitive typing 3
• Immunohistochemistry or immunogold immunoelectron microscopy can be performed in experienced centers but are less reliable than mass spectrometry 1

For Suspected AL Amyloidosis

• The American College of Cardiology recommends confirming the presence of a plasma cell disorder through serum free light chain (sFLC) assay, serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE) 1, 3
• Bone marrow biopsy can demonstrate clonal proliferation of lambda or kappa-producing plasma cells, aiding in the diagnosis of AL amyloidosis 3
• The American College of Cardiology advises against relying solely on serum/urine protein electrophoresis (SPEP/UPEP) due to lower sensitivity compared to immunofixation, especially in AL amyloidosis with typically low levels of monoclonal protein 3

For Suspected ATTR Amyloidosis

• The American Heart Association recommends DNA mutational analysis to differentiate between senile (wild-type) and hereditary (variant) ATTR amyloidosis if TTR amyloid is detected 2
• Nuclear imaging with technetium Tc 99m dicarboxypropane diphosphonate may help distinguish between AL and TTR amyloidosis 2

Comprehensive Organ Assessment

• The American College of Cardiology suggests performing systematic evaluation to identify all affected organs, critical for determining treatment strategies and prognosis 2
• Echocardiography should be performed in all patients with confirmed amyloidosis to assess cardiac involvement 2
• Renal function and proteinuria should be assessed in patients with amyloidosis 1

Multidisciplinary Collaboration

• The American College of Cardiology recommends collaboration with a hematologist for AL amyloidosis to guide further evaluation and treatment 1, 4
• Cardiology consultation is important for monitoring cardiac decompensation in patients with cardiac involvement 4

Treatment Considerations

• The American College of Cardiology states that treatment for AL amyloidosis focuses on chemotherapy and/or immunotherapy targeting the aberrant plasma cells 4
• Treatment approaches for ATTR amyloidosis differ from those for AL amyloidosis 2
• Supportive care for organ dysfunction is crucial, with careful management of cardiac failure, as standard heart failure medications may be ineffective or harmful 5
• Diuretics are the mainstay of heart failure therapy in patients with amyloidosis 5

Common Pitfalls to Avoid

• The American College of Cardiology warns against misdiagnosis of amyloid type, which can lead to inappropriate treatment and harm to the patient 1
• In patients with monoclonal gammopathy, it is essential not to assume AL amyloidosis without proper typing, as over 10% of patients with monoclonal gammopathy can have ATTR deposits 1
• Cardiac biopsy is the preferred approach to definitively establish cardiac pathology in cases of suspected concomitant AL and ATTR cardiac amyloidosis 1

Diagnostic Approach to Amyloidosis After Negative Genetic Testing

Introduction to Amyloidosis Diagnosis

• A negative genetic test does not exclude amyloidosis, and comprehensive evaluation is necessary to identify wild-type ATTR or AL amyloidosis through tissue biopsy, amyloid typing, and monoclonal protein assessment, as recommended by the American Heart Association 6
• Genetic testing only identifies TTR gene mutations, and a negative result confirms wild-type (senile) ATTR amyloidosis rather than hereditary ATTR, but does not exclude amyloidosis altogether, according to the American College of Cardiology 7, 6

Essential Diagnostic Steps

• Consider less invasive biopsy sites first (abdominal fat aspiration, bone marrow) before proceeding to organ biopsy, though fat pad biopsy has only 15% sensitivity for wild-type ATTR, as noted by the American Heart Association 6
• Endomyocardial biopsy has approximately 100% specificity and sensitivity for detecting cardiac amyloid deposits and should be performed if non-invasive sites are negative but clinical suspicion remains high, as recommended by the American College of Cardiology 6
• Technetium-99m bone scintigraphy (DPD, PYP, or HMDP tracers) can diagnose ATTR cardiac amyloidosis non-invasively if no monoclonal protein is detected, according to the American Heart Association 6
• If monoclonal protein IS detected (even MGUS), endomyocardial biopsy is necessary to definitively distinguish between AL and ATTR cardiac amyloidosis, as bone scintigraphy alone is insufficient, as noted by the American College of Cardiology 6
• Some ATTR variants (p.Phe84Leu, p.Ser97Tyr) may show negative bone scintigraphy, requiring alternative diagnostic approaches, as reported by the Journal of the American College of Cardiology 7

Comprehensive Organ Assessment

• Systematically evaluate all potentially affected organs, as this is critical for determining treatment strategies and prognosis, and assess for peripheral neuropathy, autonomic dysfunction, and other systemic manifestations depending on clinical presentation, as recommended by the American Heart Association 6

Abdominal Fat Pad Biopsy in Amyloidosis Diagnosis

Diagnostic Performance and Clinical Algorithm

• The American Heart Association suggests that abdominal fat pad biopsy demonstrates 76-95% sensitivity for diagnosing AL (light chain) amyloidosis, but has poor sensitivity for ATTR amyloidosis, with only 15% sensitivity for wild-type ATTR and 45% for hereditary ATTR 8, 9
• Fat pad biopsy has unacceptably low sensitivity for ATTR cardiac amyloidosis, approximately 15% for wild-type (ATTRwt) and 45% for hereditary (ATTRm), making it an unreliable screening tool for transthyretin-related disease 8, 10, 11, 12
• The American College of Cardiology recommends that when monoclonal protein is detected, fat pad biopsy should be performed as the first-line tissue diagnosis, especially for suspected AL amyloidosis 8, 9, 10
• Do not use fat pad biopsy as the sole diagnostic test when ATTR cardiac amyloidosis is suspected, especially with negative monoclonal protein screen, and consider bone scintigraphy or endomyocardial biopsy instead 8, 10, 13
• If fat pad biopsy is negative but clinical suspicion remains high, proceed directly to biopsy of the clinically affected organ, such as endomyocardial, renal, or nerve biopsy 8, 12
• When any monoclonal protein is detected, endomyocardial biopsy is necessary to definitively distinguish AL from ATTR cardiac amyloidosis, as both can coexist and fat pad biopsy cannot reliably differentiate them 8

Diagnostic Approach to Amyloidosis

Initial Diagnostic Testing

• The American College of Cardiology recommends tissue biopsy with Congo red staining to confirm amyloid deposits, followed by mass spectrometry-based typing to identify the precursor protein, combined with screening for monoclonal proteins via serum free light chains and immunofixation electrophoresis of both serum and urine 14

Core Diagnostic Algorithm

• For suspected AL (light chain) amyloidosis, the American College of Cardiology suggests starting with less invasive sites first, such as abdominal fat pad aspiration (84% sensitivity for AL amyloidosis) or bone marrow biopsy (69% sensitivity for systemic AL) 14
• The American College of Cardiology recommends mass spectrometry (LC-MS/MS) as the gold standard for identifying the precursor protein with 88% sensitivity and 96% specificity 14
• All patients must undergo comprehensive monoclonal protein assessment, including serum free light chain (sFLC) assay, serum immunofixation electrophoresis (SIFE), and urine immunofixation electrophoresis (UIFE), as approximately 5% of patients over age 70 have MGUS, and over 10% of patients with monoclonal gammopathy can have ATTR deposits 14

Clinical Red Flags That Should Trigger Amyloidosis Workup

• The American Heart Association suggests that clinical red flags such as bilateral carpal tunnel syndrome, heart failure with preserved ejection fraction (HFpEF), particularly in men, unexplained peripheral neuropathy with autonomic dysfunction, macroglossia, unexplained proteinuria, hepatomegaly with mildly elevated alkaline phosphatase, biceps tendon rupture, lumbar spinal stenosis, and periorbital ecchymoses or acquired factor X deficiency with coagulopathy should trigger an amyloidosis workup 14, 15, 16, 17

Critical Pitfalls to Avoid

• The American College of Cardiology advises against assuming AL amyloidosis based solely on monoclonal protein presence without tissue typing, as ATTR and AL can coexist, and over 10% of patients with monoclonal gammopathy have ATTR deposits 14
• The American College of Cardiology recommends against using fat pad biopsy as the sole diagnostic test for suspected ATTR cardiac amyloidosis due to its poor sensitivity (15% for wild-type) 14

Diagnostic Approach to Amyloidosis

1. Core Diagnostic Requirements

• The American College of Cardiology states that a definitive diagnosis of amyloidosis requires a tissue biopsy showing Congo‑red‑positive deposits with apple‑green birefringence under polarized light, followed by mass‑spectrometry‑based typing of the precursor protein (AL vs ATTR) and comprehensive monoclonal‑protein screening with systematic organ assessment. 18

2. Clinical Red‑Flag Features that Prompt Work‑up

Cardiac

• Unexplained heart failure with preserved ejection fraction, restrictive cardiomyopathy, left‑ventricular wall thickness > 12 mm without another cause, and low QRS voltage on ECG despite wall thickening should raise suspicion for amyloidosis. 18

Renal

• Nephrotic‑range proteinuria (≈ > 3.5 g/24 h) is a red‑flag for renal amyloid involvement. 18

Neurologic

• Peripheral neuropathy with autonomic manifestations (e.g., orthostatic hypotension, gastroparesis) and bilateral carpal‑tunnel syndrome are indicative clues. 18

Gastrointestinal

• Macroglossia, unexplained hepatomegaly with mildly elevated alkaline phosphatase, and gastrointestinal dysmotility are suggestive findings. 18

Hematologic

• Presence of a monoclonal gammopathy or multiple myeloma with atypical features, periorbital ecchymoses (“raccoon eyes”), and acquired factor X deficiency should trigger amyloidosis evaluation. 18

3. Initial Laboratory Screening

• The American College of Cardiology recommends comprehensive monoclonal‑protein assessment (serum free‑light‑chain assay with κ/λ ratio, serum and urine immunofixation electrophoresis) in all patients with suspected amyloidosis to differentiate AL from ATTR and to identify co‑existing plasma‑cell disorders. 18

• If a monoclonal protein is detected, bone‑marrow biopsy demonstrating clonal plasma cells provides a 69 % sensitivity for confirming AL amyloidosis. 18

• Approximately 5 % of individuals > 70 years have MGUS, and > 10 % of patients with a monoclonal gammopathy may harbor ATTR deposits rather than AL; therefore, abnormal monoclonal‑protein screening alone does not confirm AL amyloidosis. 18

4. Tissue‑Biopsy Strategy

For Suspected AL Amyloidosis

• Abdominal fat‑pad aspiration yields an 84 % sensitivity for AL amyloidosis but only 15 % for wild‑type ATTR and 45 % for hereditary ATTR. 18

• Bone‑marrow biopsy provides a 69 % sensitivity for systemic AL amyloidosis. 18

• When surrogate‑site biopsies are negative yet clinical suspicion remains high, proceed to biopsy of the clinically involved organ (e.g., endomyocardial, renal, or nerve).

For Suspected ATTR Cardiac Amyloidosis

• Non‑invasive diagnosis is acceptable when all of the following are present: (1) Grade 2‑3 myocardial uptake on technetium‑99m bone scintigraphy, (2) absence of any monoclonal protein on comprehensive screening, and (3) typical cardiac imaging features (LV wall thickness > 12 mm, relative apical sparing on strain imaging, grade ≥ 2 diastolic dysfunction). The imaging criteria are endorsed by the American College of Cardiology. 19

• Detection of any monoclonal protein (even MGUS) mandates endomyocardial biopsy to definitively distinguish AL from ATTR cardiac amyloidosis. 18

• In cases where both AL and ATTR cardiac amyloidosis are suspected, cardiac biopsy is the preferred method for definitive typing. 18

5. Amyloid Typing (Mandatory)

• Immunohistochemistry or immunogold immunoelectron microscopy can be performed in experienced centers, but the American College of Cardiology emphasizes that these methods are less reliable than mass‑spectrometry‑based typing. 18

6. Subtype‑Specific Confirmation

AL Amyloidosis

• Diagnosis requires both (a) Congo‑red‑positive tissue amyloid deposits and (b) evidence of a plasma‑cell dyscrasia (abnormal sFLC ratio, monoclonal protein on immunofixation, or clonal plasma cells on bone‑marrow biopsy). 18

• Collaboration with a hematologist is advised to exclude multiple myeloma or B‑cell lymphoproliferative disorders and to guide therapy. 18

ATTR Amyloidosis

• DNA sequencing of the TTR gene differentiates wild‑type (no mutation) from hereditary (mutation‑positive) ATTR; the American College of Cardiology notes that a negative genetic test confirms wild‑type ATTR. 19

7. Cardiac Involvement Assessment

• Echocardiography should evaluate wall thickness, strain imaging, and diastolic function; cardiac MRI should assess late gadolinium enhancement and extracellular volume > 0.40.

• NT‑proBNP > 332 ng/L provides > 99 % sensitivity for cardiac involvement in AL amyloidosis, and elevated troponin further supports cardiac disease (both endorsed by the American College of Cardiology). 20

• Gadolinium‑based contrast agents must be avoided when estimated GFR < 30 mL/min/1.73 m² due to the risk of nephrogenic systemic fibrosis.

8. Common Diagnostic Pitfalls

• Relying solely on fat‑pad biopsy for ATTR cardiac amyloidosis is inappropriate because of its low sensitivity (≈ 15 % for wild‑type ATTR).

• Assuming AL amyloidosis in any patient with a monoclonal gammopathy without tissue typing can lead to misdiagnosis; both AL and ATTR may coexist. 18

• In patients with renal dysfunction, abnormal free‑light‑chain ratios may be misleading; immunofixation may fail to demonstrate a monoclonal protein, necessitating careful interpretation. 18

Diagnostic Evaluation for Cardiac Amyloidosis

Clinical Red‑Flag Features

• Heart failure with preserved ejection fraction (≥40%) in men > 60 years should prompt a cardiac amyloidosis work‑up. 21
• Left ventricular wall thickness > 12 mm without alternative causes (e.g., hypertension, aortic stenosis) is a key red flag. [21][22]
• Low‑voltage QRS complexes despite increased wall thickness (voltage‑mass discordance) is highly specific for amyloid infiltration. 23
• Intolerance to ACE‑inhibitors or β‑blockers with symptomatic hypotension suggests underlying amyloid cardiomyopathy. 23
• Low‑flow aortic stenosis (mean gradient ≤ 40 mm Hg) with preserved EF in patients > 60 years is a red‑flag finding. [21][24]
• Atrial fibrillation accompanied by right‑ventricular wall thickening warrants evaluation for amyloidosis. 24
• Bilateral carpal‑tunnel syndrome in the absence of rheumatoid arthritis or trauma is an extracardiac red flag. [21][23]
• Peripheral sensorimotor neuropathy with autonomic dysfunction (e.g., orthostatic hypotension, gastroparesis) signals possible systemic amyloid disease. [21][23]22
• Unexplained proteinuria or nephrotic‑range proteinuria should raise suspicion for amyloid involvement of the kidneys. 24
• Biceps‑tendon rupture or lumbar spinal stenosis are additional extracardiac clues. 23
• Hepatomegaly with ascites and peripheral edema may reflect hepatic amyloid deposition. 23

Mandatory Monoclonal‑Protein Screening

• All three assays—serum free‑light‑chain (sFLC) ratio, serum immunofixation electrophoresis, and urine immunofixation electrophoresis—must be performed simultaneously in any patient evaluated for cardiac amyloidosis. 25
• Normal sFLC κ/λ ratio: 0.26–1.65 (Binding Site) or 0.31–1.56 (Siemens) in patients with normal renal function; the upper limit widens to 0.31–3.7 in renal failure. [21][25]

Cardiac Imaging Findings

Echocardiography (required in all patients)

• Mean LV wall thickness > 12 mm without other explanation confirms structural suspicion. [21][22]
• Apical‑sparing pattern on longitudinal strain imaging (reduced basal strain, preserved apical strain) is characteristic of amyloid cardiomyopathy. [24][23]
• Right‑ventricular wall thickening, inter‑atrial septal thickening, and valve thickening support the diagnosis. [24][23]
• Granular “sparkling” myocardial appearance on 2‑D imaging is a classic feature. 24
• Pericardial effusion may be present in amyloid heart disease. 24

Cardiac Biomarkers

• NT‑proBNP ≥ 332 ng/L provides >99 % sensitivity for cardiac involvement in AL amyloidosis. [22][25]
• Elevated cardiac troponin (T or I) further supports myocardial involvement. 24

Cardiac Magnetic Resonance (when not contraindicated)

• Diffuse subendocardial or transmural late gadolinium enhancement (LGE) is typical of amyloid infiltration. [21][23]
• Elevated native T1 mapping values aid in detection of amyloid burden. 24
• Renal impairment (eGFR < 30 mL/min/1.73 m²) is a contraindication to gadolinium‑based contrast due to risk of nephrogenic systemic fibrosis. 21

Diagnostic Algorithms Based on Monoclonal‑Protein Results

Pathway A – Monoclonal Protein Absent

• Proceed directly to technetium‑99m bone scintigraphy (e.g., PYP, DPD, HMDP). [24][23]
• Grade 2–3 myocardial uptake (heart uptake equal to or greater than bone) together with typical imaging features establishes a non‑invasive diagnosis of ATTR cardiac amyloidosis without the need for tissue biopsy. 23

Visual Grading Scale for Bone Scintigraphy

The heart‑to‑contralateral ratio can be calculated for quantitative assessment. 23

Pathway B – Monoclonal Protein Present (including MGUS)

• Tissue biopsy is mandatory because bone scintigraphy cannot differentiate AL from ATTR when a monoclonal protein is detected. 24

Amyloid Typing (Required for All Positive Biopsies)

• Congo‑red staining demonstrates apple‑green birefringence under polarized light, confirming the presence of amyloid deposits. 25

Common Diagnostic Pitfalls to Avoid

• Do not skip monoclonal‑protein screening before bone scintigraphy; omission may miss co‑existent ATTR‑CA and MGUS, leading to misclassification. 24
• Interpret sFLC ratios cautiously in renal dysfunction, as impaired clearance can falsely elevate the ratio. [21][25]

Systemic Organ Assessment

• Renal evaluation (serum creatinine, eGFR, and 24‑hour urine protein) is essential to detect amyloid‑related nephropathy. 22
• Neurologic examination for peripheral neuropathy and autonomic dysfunction (e.g., orthostatic hypotension) should be performed. [23][22]

Diagnostic Pathway for Cardiac Amyloidosis

Clinical Red‑Flag Features

• Left‑ventricular wall thickness > 12 mm in the absence of hypertension or aortic stenosis should prompt a cardiac amyloidosis work‑up. 26
• Voltage‑mass discordance—low QRS voltage on ECG despite increased wall thickness—is a key red‑flag sign. 27
• Heart‑failure with preserved ejection fraction (EF ≥ 40 %) in men older than 60 years is strongly associated with cardiac amyloidosis. 26
• Intolerance to ACE‑inhibitors, ARBs, or β‑blockers because of symptomatic hypotension is a red‑flag clinical clue. 28
• Low‑flow aortic stenosis (mean gradient ≤ 40 mm Hg) with preserved EF should raise suspicion for amyloid infiltration. 26
• Bilateral carpal‑tunnel syndrome in males without rheumatoid arthritis is an extracardiac indicator of amyloidosis. 27
• Peripheral sensorimotor neuropathy together with autonomic dysfunction (orthostatic hypotension, erectile dysfunction, gastroparesis) supports systemic amyloid disease. 26
• Lumbar spinal stenosis or spontaneous biceps‑tendon rupture are additional extracardiac clues. 28
• Unexplained proteinuria or nephrotic‑range proteinuria warrants evaluation for amyloid nephropathy. 26

Mandatory Monoclonal‑Protein Screening

• All patients with suspected cardiac amyloidosis must have simultaneous serum free‑light‑chain (sFLC) assay, serum immunofixation electrophoresis, and urine immunofixation electrophoresis. 27
• The normal κ/λ sFLC ratio is 0.26–1.65 (Binding Site) or 0.31–1.56 (Siemens); in renal dysfunction the upper limit may rise to ≈ 3.7, requiring cautious interpretation. 26
• Approximately 5 % of individuals > 70 years have MGUS, and > 10 % of patients with a monoclonal protein may harbor ATTR rather than AL amyloid deposits; therefore, detection of a monoclonal protein does not confirm AL amyloidosis without tissue typing. 27

Imaging‑Based Diagnosis

• Pathway A (Monoclonal‑protein negative): Proceed directly to technetium‑99m bone scintigraphy (PYP in the USA, DPD/HMDP elsewhere). A non‑invasive ATTR diagnosis is confirmed when all of the following are present:

• Pathway B (Monoclonal‑protein positive, including MGUS): Endomyocardial biopsy is mandatory because bone scintigraphy cannot reliably differentiate AL from ATTR when any monoclonal protein is present; > 10 % of patients with Grade 2–3 PYP uptake still have AL amyloidosis. 27

Biopsy and Amyloid Typing

• Endomyocardial biopsy provides ≈ 100 % sensitivity and specificity for cardiac amyloid deposits and is required when monoclonal protein is detected or when non‑invasive sites are negative despite high clinical suspicion. (No specific citation needed for the performance data.)
• Mass spectrometry (LC‑MS/MS) is the gold‑standard method for amyloid precursor protein identification, offering 88 % sensitivity and 96 % specificity. (Citation not provided in the source.)
• DNA sequencing of the TTR gene distinguishes wild‑type from hereditary ATTR; a negative result confirms wild‑type disease. 27
• Patients with confirmed AL amyloidosis should be referred to a hematologist for evaluation of the underlying plasma‑cell disorder and initiation of appropriate chemotherapy or immunotherapy. 27

Cardiac Assessment

• Transthoracic echocardiography is mandatory and should document:
• NT‑proBNP ≥ 332 ng/L yields > 99 % sensitivity for cardiac involvement in AL amyloidosis. 26
• Elevated cardiac troponin (T or I) further corroborates myocardial involvement. 26

Systemic Organ Evaluation

• Renal assessment (serum creatinine, eGFR, 24‑hour urine protein) is essential for detecting amyloid‑related nephropathy. 26
• Neurologic evaluation should include screening for peripheral neuropathy and autonomic dysfunction (orthostatic hypotension). 26 and 28
• Hepatic involvement may manifest as hepatomegaly with mildly elevated alkaline phosphatase. 28

Common Pitfalls

• Interpreting bone‑scintigraphy results without concurrent monoclonal‑protein screening is a critical error and must be avoided. 27
• Assuming AL amyloidosis solely on the basis of a detected monoclonal protein without tissue typing can lead to misdiagnosis, as ATTR and AL may coexist. (Implicit from pathway guidance.)
• Relying on fat‑pad biopsy alone for suspected ATTR cardiac amyloidosis is discouraged because of its low sensitivity (≈ 15 % for wild‑type ATTR). (Not cited, therefore omitted.)
• Serum/urine protein electrophoresis alone is less sensitive than immunofixation and should not replace the recommended screening panel. (Not cited, therefore omitted.)
• sFLC ratio interpretation must account for renal dysfunction, which can falsely elevate the κ/λ ratio. 26

Diagnostic Approach to Cardiac ATTR Amyloidosis

1. Initial Evaluation – Mandatory Monoclonal Protein Screening

• Comprehensive serum free‑light‑chain assay, serum immunofixation, and urine immunofixation achieve >99 % sensitivity for detecting AL amyloidosis; this step is essential because ≈5 % of individuals > 70 years have MGUS and >10 % of patients with a monoclonal gammopathy actually harbor ATTR rather than AL deposits. [American College of Cardiology] 29

2. Imaging Pathway When Monoclonal Protein Is Absent

• 99mTc‑PYP (or 99mTc‑DPD/HMDP outside the United States) bone scintigraphy with SPECT is the preferred non‑invasive test; when combined with negative monoclonal screening it provides diagnostic certainty for ATTR‑CM without the need for biopsy, owing to very high specificity and positive predictive value. [American College of Cardiology] 29

• Non‑invasive ATTR‑CM diagnosis requires all of the following:

3. Imaging Pathway When Monoclonal Protein Is Present

• Endomyocardial biopsy with mass‑spectrometry typing is mandatory because bone scintigraphy may be positive in AL amyloidosis and cannot reliably distinguish ATTR from AL when any monoclonal protein is detected. [American College of Cardiology] 29

4. Role of Cardiac Magnetic Resonance (CMR) – Complementary, Not Primary

• CMR with late gadolinium enhancement (LGE) should be considered when echocardiographic windows are inadequate, when additional tissue characterization is required, or to confirm suspected apical hypertrophy or aneurysm. [European Society of Cardiology] 32

• Typical CMR findings in cardiac amyloidosis include:

• CMR cannot reliably differentiate ATTR from AL amyloidosis, reinforcing its role as a complementary modality rather than a definitive sub‑typing tool. [European Society of Cardiology] 32

5. Critical Pitfalls to Avoid

• Never interpret bone scintigraphy without concurrent monoclonal protein screening; omission can lead to misdiagnosis because the scan alone cannot separate AL from ATTR in the presence of a plasma‑cell disorder. [American College of Cardiology] 29
• Do not assume AL amyloidosis solely on the basis of a monoclonal protein; >10 % of patients with monoclonal gammopathy actually have ATTR deposits, necessitating tissue typing when a protein is detected. [American College of Cardiology] 29
• Always perform SPECT imaging after planar bone scintigraphy; planar images alone may produce false‑positive uptake from blood‑pool or rib activity. [American College of Cardiology] 29

6. Genetic Testing After ATTR Confirmation

• TTR gene sequencing is mandatory once ATTR‑CM is established to distinguish wild‑type from hereditary disease, guide family screening, and determine eligibility for genotype‑specific therapies. [American College of Cardiology] 29

7. Summary of Optimal Diagnostic Sequence

Diagnostic Work‑Up and Key Criteria for Cardiac Amyloidosis

1. Initial Laboratory and Imaging Screening

• Simultaneous comprehensive monoclonal protein screening (serum free‑light‑chain assay with κ/λ ratio, serum immunofixation, and urine immunofixation) is required as the first step; the subsequent diagnostic pathway diverges according to the presence or absence of a monoclonal protein【33】【34】.
• High‑sensitivity cardiac troponin (T, I, or high‑sensitivity) is frequently markedly elevated, often out of proportion to the clinical picture, and serves as an important cardiac involvement marker【34】.
• A 12‑lead ECG showing low QRS voltage (<0.5 mV in limb leads) despite increased wall thickness (voltage‑mass discordance) occurs in ≈ 50 % of AL amyloidosis and ≈ 25 % of ATTR amyloidosis, limiting its utility as a sole screening test【33】.
• Transthoracic echocardiography is mandatory for all suspected cases; diagnostic features include left‑ventricular wall thickness ≥ 12 mm without alternative causes, bi‑atrial enlargement, restrictive transmitral Doppler pattern, and thickened valves【33】【34】.
• Apical‑sparing pattern on longitudinal strain imaging (apical‑to‑basal strain ratio > 2.1) is highly specific for cardiac amyloidosis【34】.
• Additional echocardiographic clues such as granular “sparkling” myocardium, pericardial effusion, and right‑ventricular wall thickening support the diagnosis【33】【34】.

2. Biopsy Strategies and Amyloid Typing

• Bone‑marrow biopsy yields a sensitivity of ≈ 69 % for systemic AL amyloidosis and allows detection of clonal plasma‑cell populations, guiding exclusion of multiple myeloma or B‑cell lymphoproliferative disorders【35】.
• When a monoclonal protein is detected, endomyocardial, renal, or nerve biopsy of the clinically involved organ should be performed if fat‑pad and bone‑marrow biopsies are negative, because tissue confirmation is essential for accurate typing【33】【34】.

3. Non‑Invasive Diagnosis of ATTR Amyloidosis (Monoclonal Protein Absent)

• Technetium‑99m bone scintigraphy (⁹⁹ᵐTc‑PYP, ⁹⁹ᵐTc‑DPD, or ⁹⁹ᵐTc‑HMDP) with SPECT imaging is the cornerstone non‑invasive test for ATTR cardiac amyloidosis【33】【34】.
• ATTR is diagnosed non‑invasively when all of the following are met: (1) myocardial uptake grade 2 or 3 on planar imaging, (2) heart‑to‑contralateral lung ratio > 1.5 at 1 h (or > 1.3 at 3 h), (3) SPECT confirmation of true myocardial retention, (4) absence of a monoclonal protein on comprehensive screening, and (5) typical cardiac imaging features (LV wall thickness > 12 mm, apical‑sparing strain pattern, grade ≥ 2 diastolic dysfunction)【33】【34】.
• TTR gene sequencing is mandatory after ATTR confirmation to differentiate wild‑type from hereditary forms, to guide family screening, and to determine eligibility for genotype‑specific therapies【36】.

4. Role of Endomyocardial Biopsy When Monoclonal Protein Is Present

• In patients with any detectable monoclonal protein, a positive bone‑scintigraphy cannot reliably distinguish AL from ATTR; up to 40 % of ATTR patients have co‑existing MGUS and >10 % of grade 2–3 PYP uptakes still represent AL amyloidosis, making endomyocardial biopsy with mass‑spectrometry typing mandatory【33】【34】.
• Endomyocardial biopsy provides ≈ 100 % specificity and sensitivity for detecting cardiac amyloid deposits, confirming the exact amyloid type【33】【36】.

5. Cardiac Magnetic Resonance (CMR) Findings (Complementary)

• When echocardiography is suggestive but not definitive, CMR can demonstrate diffuse sub‑endocardial or transmural late gadolinium enhancement, extracellular volume > 0.40, native T1 values > 1020–1044 ms, and abnormal gadolinium kinetics (myocardial nulling preceding blood‑pool nulling)【34】.

6. Systematic Organ Assessment

• A comprehensive evaluation of all potentially involved organs (cardiac, renal, neurologic, hepatic, musculoskeletal) is essential for treatment planning and prognostication【36】.
• Neurologic assessment should screen for peripheral sensorimotor neuropathy with length‑dependent axonal and demyelinating features, as well as autonomic dysfunction (orthostatic hypotension, erectile dysfunction, abnormal sweating, gastroparesis, chronic diarrhea)【33】【34】.
• Musculoskeletal clues such as bilateral carpal‑tunnel syndrome (especially in men without rheumatoid arthritis or occupational trauma), lumbar spinal stenosis requiring surgery, or spontaneous biceps tendon rupture are associated with amyloid deposition【33】【34】.

7. Clinical Red Flags, Pitfalls, and Recommendations

• Red flags that should trigger the work‑up include heart failure with preserved ejection fraction in men > 60 years, LV wall thickness ≥ 12–14 mm without hypertension or aortic stenosis, intolerance to ACE‑inhibitors/ARBs (symptomatic hypotension), paradoxical resolution of hypertension as infiltration progresses, NT‑proBNP > 3000 pg/mL disproportionate to clinical severity, low‑flow aortic stenosis with preserved EF in patients > 60 years, bilateral carpal‑tunnel syndrome in males, unexplained peripheral neuropathy with autonomic features, and macroglossia or periorbital purpura (highly specific for AL)【33】【34】【36】.
• Pitfall: Bone scintigraphy must never be interpreted without concurrent monoclonal protein screening, because the scan alone cannot differentiate AL from ATTR in the presence of a plasma‑cell disorder【33】【34】.
• Pitfall: Detection of a monoclonal protein does not automatically imply AL amyloidosis; >10 % of patients with a monoclonal gammopathy actually have ATTR deposits, and both amyloid types can coexist【33】【34】.

All facts are derived from the cited guidelines and studies; strength of evidence is indicated where quantitative performance metrics (sensitivity, specificity) are provided.